Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma

MT Newswires Live06-15

Genscript Biotech (HKG:1548) said its Nasdaq-listed associate Legend Biotech established clinical proof-of-concept for LB2501 in a type of blood cancer, according to a Sunday filing with the Hong Kong bourse.

According to results from an ongoing phase 1 trial presented at the annual European Hematology Association Congress, the drug achieved a 100% objective response rate at the higher dose level in the six subjects enrolled in the study with relapsed or refractory B-cell non-Hodgkin lymphoma.

LB2501 also showed a favorable safety profile with no dose-limiting toxicities, the firm said.

Shares of Genscript fell almost 9% in late morning trade on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643212252?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 11:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643212252","market":"us","top_or_hot":-1,"title":"Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GNNSF\">Genscript Biotech</a> (HKG:1548) said its Nasdaq-listed associate Legend Biotech established clinical proof-of-concept for LB2501 in a type of blood cancer, according to a Sunday filing with the Hong Kong bourse.</p><p>According to results from an ongoing phase 1 trial presented at the annual European Hematology Association Congress, the drug achieved a 100% objective response rate at the higher dose level in the six subjects enrolled in the study with relapsed or refractory B-cell non-Hodgkin lymphoma.</p><p>LB2501 also showed a favorable safety profile with no dose-limiting toxicities, the firm said.</p><p>Shares of Genscript fell almost 9% in late morning trade on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-15 11:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GNNSF\">Genscript Biotech</a> (HKG:1548) said its Nasdaq-listed associate Legend Biotech established clinical proof-of-concept for LB2501 in a type of blood cancer, according to a Sunday filing with the Hong Kong bourse.</p><p>According to results from an ongoing phase 1 trial presented at the annual European Hematology Association Congress, the drug achieved a 100% objective response rate at the higher dose level in the six subjects enrolled in the study with relapsed or refractory B-cell non-Hodgkin lymphoma.</p><p>LB2501 also showed a favorable safety profile with no dose-limiting toxicities, the firm said.</p><p>Shares of Genscript fell almost 9% in late morning trade on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643212252","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643212252","pubTimestamp":1781495219,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genscript Biotech  said its Nasdaq-listed associate Legend Biotech established clinical proof-of-concept for LB2501 in a type of blood cancer, according to a Sunday filing with the Hong Kong bourse.According to results from an ongoing phase 1 trial presented at the annual European Hematology Association Congress, the drug achieved a 100% objective response rate at the higher dose level in the six subjects enrolled in the study with relapsed or refractory B-cell non-Hodgkin lymphoma.LB2501 also showed a favorable safety profile with no dose-limiting toxicities, the firm said.Shares of Genscript fell almost 9% in late morning trade on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1576":"医药外包概念","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","01548":"金斯瑞生物科技","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"Genscript Associate报告了LB2501治疗B细胞淋巴瘤的有希望的1期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech (HKG:1548) said its Nasdaq-listed associate Legend Biotech established clinical proof-of-concept for LB2501 in a type of blood cancer, according to a Sunday filing with the Hong Kong bourse.According to results from an ongoing phase 1 trial presented at the annual European Hematology Association Congress, the drug achieved a 100% objective response rate at the higher dose level in the six subjects enrolled in the study with relapsed or refractory B-cell non-Hodgkin lymphoma.LB2501 also showed a favorable safety profile with no dose-limiting toxicities, the firm said.Shares of Genscript fell almost 9% in late morning trade on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643212252","isCrawlerRequest":true}